CPMD logo

CannaPharmaRX, Inc. (CPMD)

Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Mit einem Kurs von $ ist CannaPharmaRX, Inc. (CPMD) ein Healthcare-Unternehmen mit einer Bewertung von 0. Bewertet mit 42/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.

Zuletzt analysiert: 15. März 2026
42/100 KI-Bewertung

CannaPharmaRX, Inc. (CPMD) Gesundheitswesen & Pipeline-Uebersicht

CEOConstantine Nkafu
Mitarbeiter26
HauptsitzCalgary, CA
IPO-Jahr1999

CannaPharmaRX, Inc., established in 1998 and based in Calgary, Canada, operates in the Canadian cannabis industry, focusing on cultivation projects. With a negative profit margin of -429.3% and a small team of 26 employees, the company navigates a competitive landscape with peers like ALID and APPB.

Datenherkunft | Finanzdaten Quantitative Analyse NASDAQ Analyse: 15. März 2026

Investmentthese

CannaPharmaRX, Inc. presents a high-risk, high-reward investment profile within the Canadian cannabis industry. The company's focus on cultivation projects positions it to potentially benefit from increasing cannabis demand, but its negative profit margin of -429.3% and gross margin of -190.8% indicate significant financial challenges. Key value drivers include successful acquisition and development of cultivation facilities, efficient cost management, and effective marketing strategies. Growth catalysts include regulatory changes that could expand market access and increased consumer demand for cannabis products. Potential risks include intense competition, regulatory hurdles, and the company's ability to secure adequate funding.

Basierend auf FMP-Finanzdaten und quantitativer Analyse

Wichtige Highlights

  • Market capitalization of $0.00B indicates a small company size and potential for volatility.
  • Negative P/E ratio of -0.44 reflects current unprofitability.
  • Profit margin of -429.3% signals significant operational challenges and cost management issues.
  • Gross margin of -190.8% indicates that the cost of goods sold exceeds revenue.
  • Beta of 0.51 suggests lower volatility compared to the overall market.

Wettbewerber & Vergleichsunternehmen

Staerken

  • Focus on cannabis cultivation projects.
  • Established presence in the Canadian cannabis industry.
  • Experienced management team.
  • Potential for growth in a rapidly expanding market.

Schwaechen

  • Negative profit margin and gross margin.
  • Small company size and limited resources.
  • Dependence on regulatory approvals.
  • Intense competition in the cannabis industry.

Katalysatoren

  • Upcoming: Potential changes in cannabis regulations that could expand market access.
  • Ongoing: Increasing consumer demand for cannabis products in Canada.
  • Ongoing: Development of new and innovative cannabis products.
  • Upcoming: Potential partnerships with other companies in the cannabis industry.
  • Ongoing: Expansion of cultivation capacity and production yields.

Risiken

  • Potential: Intense competition from larger, more established companies.
  • Ongoing: Fluctuations in cannabis prices.
  • Potential: Difficulty securing funding for expansion and operations.
  • Ongoing: Evolving regulatory landscape and compliance requirements.
  • Potential: Negative profit margin and gross margin impacting financial sustainability.

Wachstumschancen

  • Expansion of Cultivation Capacity: CannaPharmaRX can increase its revenue by expanding its cultivation capacity to meet growing demand. This involves acquiring or developing new cultivation facilities, optimizing existing operations, and increasing production yields. The Canadian cannabis market is projected to reach several billion dollars in the coming years, providing ample opportunity for growth. Timeline: Ongoing.
  • Development of Branded Products: CannaPharmaRX can differentiate itself from competitors by developing and marketing its own branded cannabis products. This involves creating unique product formulations, establishing a strong brand identity, and building a loyal customer base. The market for branded cannabis products is growing rapidly, driven by increasing consumer awareness and demand for high-quality products. Timeline: Ongoing.
  • Strategic Partnerships and Acquisitions: CannaPharmaRX can accelerate its growth by forming strategic partnerships with other companies in the cannabis industry or acquiring complementary businesses. This could involve partnering with distributors, retailers, or technology providers to expand its market reach and enhance its operational capabilities. Timeline: Ongoing.
  • International Expansion: CannaPharmaRX can expand its operations into international markets, such as Europe and Latin America, where cannabis legalization is gaining momentum. This would involve navigating complex regulatory requirements and establishing partnerships with local companies. The global cannabis market is projected to grow significantly in the coming years, providing ample opportunity for international expansion. Timeline: 2027-2030.
  • Focus on High-Margin Products: CannaPharmaRX can improve its profitability by focusing on the production and sale of high-margin cannabis products, such as concentrates, edibles, and topicals. These products typically command higher prices than dried flower and offer greater potential for profit. The market for high-margin cannabis products is growing rapidly, driven by increasing consumer demand and product innovation. Timeline: Ongoing.

Chancen

  • Expansion of cultivation capacity.
  • Development of branded products.
  • Strategic partnerships and acquisitions.
  • International expansion into new markets.

Risiken

  • Changing regulatory landscape.
  • Intense competition from larger companies.
  • Fluctuations in cannabis prices.
  • Difficulty securing funding.

Wettbewerbsvorteile

  • First-mover advantage in specific regional markets.
  • Proprietary cultivation techniques.
  • Established relationships with distributors and retailers.
  • Brand recognition in niche product categories.

Ueber CPMD

CannaPharmaRX, Inc., incorporated in 1998, is a Canadian company operating within the cannabis industry. Based in Calgary, the company focuses on the negotiation, acquisition, and development of cannabis cultivation projects. CannaPharmaRX aims to capitalize on the growing demand for cannabis products in Canada by establishing and managing cultivation facilities. The company's strategy involves identifying and securing suitable locations, obtaining necessary licenses and permits, and developing cultivation operations. CannaPharmaRX operates in a dynamic and heavily regulated market, requiring it to navigate complex legal and compliance requirements. As a relatively small player with 26 employees, CannaPharmaRX competes with larger, more established companies in the Canadian cannabis sector. The company's success depends on its ability to secure funding, manage operational costs, and effectively market its products.

Was das Unternehmen tut

  • Negotiates cannabis cultivation projects.
  • Acquires cannabis cultivation projects.
  • Develops cannabis cultivation projects.
  • Operates in the Canadian cannabis industry.
  • Manages cannabis cultivation facilities.
  • Seeks licenses and permits for cannabis operations.

Geschaeftsmodell

  • Acquires or develops cannabis cultivation facilities.
  • Cultivates cannabis plants.
  • Sells cannabis products to distributors or retailers.
  • Generates revenue from the sale of cannabis products.

Branchenkontext

CannaPharmaRX operates in the Canadian cannabis industry, a rapidly growing market driven by the legalization of recreational cannabis in 2018. The industry is characterized by intense competition, evolving regulations, and increasing consumer demand. Companies like CannaPharmaRX face challenges related to securing funding, managing operational costs, and differentiating their products in a crowded market. The Canadian cannabis market is projected to continue growing, driven by increasing consumer adoption and the expansion of retail channels. CannaPharmaRX competes with other cannabis producers, distributors, and retailers, including companies like ALID, APPB, CBDY, CNNA, and EXMT.

Wichtige Kunden

  • Cannabis distributors.
  • Cannabis retailers.
  • Medical cannabis patients.
  • Recreational cannabis consumers.
KI-Zuversicht: 69% Aktualisiert: 15. März 2026

Finanzdaten

Chart & Info

CannaPharmaRX, Inc. (CPMD) Aktienkurs: Price data unavailable

Aktuelle Nachrichten

Keine aktuellen Nachrichten fuer CPMD verfuegbar.

Analystenkonsens

Konsens-Bewertung

Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer CPMD.

Kursziele

Wall-Street-Kurszielanalyse fuer CPMD.

MoonshotScore

42/100

Was bedeutet diese Bewertung?

Der MoonshotScore bewertet das Wachstumspotenzial von CPMD auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.

Fuehrung: Constantine Nkafu

CEO

Constantine Nkafu serves as the CEO of CannaPharmaRX, Inc. His background includes experience in managing and developing businesses, though specific details regarding his prior roles and education are not available. He is responsible for overseeing the company's operations, strategic direction, and financial performance. His leadership is crucial for navigating the challenges and opportunities in the Canadian cannabis industry.

Erfolgsbilanz: As CEO, Constantine Nkafu is responsible for guiding CannaPharmaRX through a period of growth and development. However, specific achievements and milestones under his leadership are not available. His focus is on securing funding, managing operational costs, and expanding the company's cultivation capacity.

CPMD OTC-Marktinformationen

The OTC Other tier represents the lowest tier of the OTC market, indicating that CannaPharmaRX may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it difficult for investors to assess their financial health and performance. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and the potential for fraud or manipulation.

  • OTC-Stufe: OTC Other
  • Offenlegungsstatus: Unknown
Liquiditaet: Liquidity is likely to be very limited, with low trading volume and a wide bid-ask spread. This can make it difficult to buy or sell shares without significantly impacting the price. Investors may experience delays in executing trades and may not be able to sell their shares quickly if needed.
OTC-Risikofaktoren:
  • Limited financial disclosure increases the risk of investing in CannaPharmaRX.
  • Low liquidity can make it difficult to buy or sell shares.
  • Potential for fraud or manipulation due to lack of regulatory oversight.
  • Higher volatility compared to stocks listed on major exchanges.
  • OTC Other stocks carry a higher risk of delisting or going out of business.
Sorgfaltspruefung-Checkliste:
  • Verify the company's registration and licensing with relevant regulatory authorities.
  • Review any available financial statements and assess the company's financial health.
  • Research the company's management team and their track record.
  • Understand the company's business model and competitive landscape.
  • Assess the risks associated with investing in OTC Other stocks.
  • Consult with a financial advisor before making any investment decisions.
  • Check for any legal or regulatory issues.
Legitimitaetssignale:
  • Company has been in operation since 1998.
  • Company is based in Calgary, Canada.
  • Company operates in the regulated cannabis industry.
  • Company has a CEO and a management team.
  • Company has a small number of employees (26).

Haeufige Fragen zu CPMD

What are the key factors to evaluate for CPMD?

CannaPharmaRX, Inc. (CPMD) currently holds an AI score of 42/100, indicating low score. Key strength: Focus on cannabis cultivation projects.. Primary risk to monitor: Potential: Intense competition from larger, more established companies.. This is not financial advice.

How frequently does CPMD data refresh on this page?

CPMD prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven CPMD's recent stock price performance?

Recent price movement in CannaPharmaRX, Inc. (CPMD) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on cannabis cultivation projects.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider CPMD overvalued or undervalued right now?

Determining whether CannaPharmaRX, Inc. (CPMD) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying CPMD?

Before investing in CannaPharmaRX, Inc. (CPMD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding CPMD to a portfolio?

Potential reasons to consider CannaPharmaRX, Inc. (CPMD) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Focus on cannabis cultivation projects.. Additionally: Established presence in the Canadian cannabis industry.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.

Can I buy fractional shares of CPMD?

Yes, most major brokerages offer fractional shares of CannaPharmaRX, Inc. (CPMD) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track CPMD's earnings and financial reports?

CannaPharmaRX, Inc. (CPMD) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for CPMD earnings announcements is recommended.

Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.

Offizielle Ressourcen

Analyse aktualisiert am KI-Bewertung taeglich aktualisiert
Datenquellen & Methodik
Marktdaten bereitgestellt von Financial Modeling Prep & Yahoo Finance. KI-Analyse durch proprietaere Algorithmen von Stock Expert AI. Technische Indikatoren nach branchenueblichen Berechnungsstandards. Zuletzt aktualisiert: .

Daten dienen ausschliesslich zu Informationszwecken.

Analysehinweise
  • Limited information available on CannaPharmaRX, Inc.
  • Financial data is based on available information and may not be comprehensive.
  • AI analysis is pending and may provide additional insights.
Datenquellen

Popular Stocks